p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET.

  title={p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET.},
  author={Melissa A Deri and Shashikanth Ponnala and Paul Kozlowski and Benjamin P. Burton‐Pye and Huseyin T. Cicek and Chunhua Tony Hu and Jason S. Lewis and Lynn C. Francesconi},
  journal={Bioconjugate chemistry},
  volume={26 12},
Zirconium-89 has an ideal half-life for use in antibody-based PET imaging; however, when used with the chelator DFO, there is an accumulation of radioactivity in the bone, suggesting that the (89)Zr(4+) cation is being released in vivo. Therefore, a more robust chelator for (89)Zr could reduce the in vivo release and the dose to nontarget tissues. Evaluation of the ligand 3,4,3-(LI-1,2-HOPO) demonstrated efficient binding of (89)Zr(4+) and high stability; therefore, we developed a bifunctional… 

Figures from this paper

Improved synthesis of the bifunctional chelator p-SCN-Bn-HOPO.

An improved and efficient synthesis of p-SCN-Bn-HOPO is reported in four steps with 14.3% overall yield which will improve its availability for further biological studies and wider application in PET imaging.

Design, Synthesis, and Evaluation of DFO-Em: A Modular Chelator with Octadentate Chelation for Optimal Zirconium-89 Radiochemistry.

In this study, a new octadentate chelator is designed, synthesized, and characterized, which is an improved derivative of the previously published dodecadentates chelator DFO2, and revealed that DFO-Em has a comparable radiolabeling profile to the gold standard chelation DFO.

Evaluation of the Tetrakis(3-Hydroxy-4-Pyridinone) Ligand THPN with Zirconium(IV): Thermodynamic Solution Studies, Bifunctionalization, and in Vivo Assessment of Macromolecular 89Zr-THPN-Conjugates.

It is demonstrated how HPG can be used as a robust carrier tool to assess and compare the long-term in vivo stability of radiochelates and inform the design of next generation 3,4-HOPO chelates with the aim of improving the physiologic stability.

Promising Performance of 4HMS, a New Zirconium-89 Octadendate Chelator

The synthesis of an acyclic N-hydroxy-N-methyl succinamide-based chelator (4HMS) with 8 coordination sites and the first investigations into the use of this new chelator for 89Zr complexation are reported, making 4HMS a promising chelation system for future development of 89ZR-radiopharmaceuticals.

Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for 89Zr4+ and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice

The newly developed 3-hydroxypyridin-2-one based di-macrocyclic chelator provides a viable alternative to DFO-based heterobifunctional ligands for preparation of 89Zr-labeled monoclonal antibodies for immunoPET studies.

The Race for Hydroxamate-Based Zirconium-89 Chelators

The progress in this research field until end of 2020 is described, including promising examples of new candidates of chelators currently in advanced stages for clinical translation that outrun the performance of the current gold standard DFO.

Trastuzumab-conjugated oxine-based ligand for [89Zr]Zr4+ immunoPET.

The primary amine platform of H4neunox developed here provides an oxine-based bifunctional ligand for further derivatizations with other targeting vectors, and lowered inertness towards serum and demetallation in vivo through bone uptake in PET imaging and biodistribution studies when compared to [89Zr]Zr(DFO-Trastuzumab).

Toward Optimized 89Zr-Immuno-PET: Side-by-Side Comparison of [89Zr]Zr-DFO-, [89Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [89Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?

DFO* currently represents the most suitable chelator candidate for stable 89Zr-radiolabeling of antibodies and clinical translation and demonstrates a very high kinetic inertness, paired with a highly favorable pharmacokinetic profile of the resulting antibody conjugate.

A solid phase-assisted approach for the facile synthesis of a highly water-soluble zirconium-89 chelator for radiopharmaceutical development.

An ether derivative, oxoDFO*, resembling the motif of DFO with four hydroxamic acid groups for the binding of the radiometal and four ether linkages to increase the water solubility is reported.

Comparative Study of a Decadentate Acyclic Chelate, HOPO-O10, and Its Octadentate Analogue, HOPO-O8, for Radiopharmaceutical Applications.

The rational design and chemical development of a novel decadentate acyclic chelate containing five 1, 2-hydroxypyridinones, 3,4,3,3-(LI-1,2-HOPO), referred to herein as HOPO-O10, based on the well-known octadentate ligand, revealed.



Alternative Chelator for 89Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)

HOPO has the potential to replace DFO as the chelator of choice for 89Zr-based PET imaging agents and lead to a safer PET tracer with reduced background radiation dose.

H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu.

It can be concluded from this work that H6phospa is not superior to the previously studied H4octapa for use with (111)In and (177)Lu, but improvements in (89)Zr radiolabeling were observed over H4 octapa, suggesting H6 phospa to be an excellent starting point for elaboration of (89]Zr-based radiopharmaceutical development.

Novel Bifunctional Cyclic Chelator for 89Zr Labeling–Radiolabeling and Targeting Properties of RGD Conjugates

Findings indicate that FSC is a highly promising chelator for the development of 89Zr-based PET imaging agents.

Rational design, synthesis, and evaluation of tetrahydroxamic acid chelators for stable complexation of zirconium(IV).

A series of tetrahydroxamic acids of varying geometries are designed for improved complexation of (89) Zr, with the best chelators providing dramatically improved stabilities compared with the reference DFB.

Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers

It was concluded that 111In(DTPA-3P-RGD2) can be an effective integrin αvβ3-targeted radiotracer if the high-specific activity is required and DOTA remains to be the BFC of choice for the development of therapeutic lanthanide drugs.

Hydroxypyridinonate complex stability of group (IV) metals and tetravalent f-block elements: the key to the next generation of chelating agents for radiopharmaceuticals.

High thermodynamic stabilities not only confirm the unparalleled Pu(IV) affinity of 3,4,3-LI(1,2-HOPO) as a decorporation agent but also corroborate the great potential of hydroxypyridinonate ligands as new (89)Zr-chelating platforms for immuno-PET applications.

Di-macrocyclic terephthalamide ligands as chelators for the PET radionuclide zirconium-89.

The first octadentate terephthalamide ligands, which are easily radiolabeled with (89)Zr and are highly stable in vitro, represent a novel class of chelators, which is worthy of further development as BFCs for (89]Zr.

Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89.

A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

A practical guide to the construction of radiometal-based PET bioconjugates, in which the design choices and synthetic details of a wide range of biomolecular tracers from the literature are collected in a single reference.